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Abstract
Background: Glucose-dependent insulinotropic polypeptide (GIP) is one of the incretins, which plays a crucial role
in the secretion of insulin upon food stimulus and in the regulation of postprandial glucose level. It also exerts an
effect on the synthesis and secretion of lipoprotein lipase, from adipocytes, important for lipid metabolism. The
aim of our study was to do a case-control association analysis of common variants in GIP in association with type 2
diabetes and related biochemical parameters.
Method: A total of 2000 subjects which includes 1000 (584M/416F) cases with type 2 diabetes and 1000 (470M/
530F) normoglycemic control subjects belonging to Dravidian ethnicity from South India were recruited to assess
the effect of single nucleotide polymorphisms (SNPs) in GIP (rs2291725, rs2291726, rs937301) on type 2 diabetes in
a case-control manner. The SNPs were genotyped by using tetra primer amplification refractory mutation system-
PCR (ARMS PCR). For statistical analysis, our study population was divided into sub-groups based on gender (male
and female). Association analysis was carried out using chi-squared test and the comparison of biochemical
parameters among the three genotypes were performed using analysis of covariance (ANCOVA).
Result: Initial analysis revealed that, out of the total three SNPs selected for the present study, two SNPs namely
rs2291726 and rs937301 were in complete linkage disequilibrium (LD) with each other. Therefore, only two SNPs,
rs2291725 and rs2291726, were genotyped for the association studies. No significant difference in the allele
frequency and genotype distribution of any of the SNPs in GIP were observed between cases and controls (P >
0.05). Analysis of biochemical parameters among the three genotypes showed a significant association of total
cholesterol (P = 0.042) and low density lipoprotein (LDL) with the G allele of the SNP rs2291726 in GIP (P = 0.004),
but this was observed only in the case of female subjects. However this association does not remain significant
after correction for multiple testing by Bonferroni’s inequality method.
Conclusion: No statistically significant association was observed between any of the SNPs analysed and type 2
diabetes in our population. But the analysis of biochemical parameters indicates that the G allele in rs2291726 may
be a putative risk allele for increased LDL cholesterol and further studies in other population needs to be carried
out for ascertaining its role in cholesterol metabolism and subsequent cardiovascular risk.
Background
Type 2 diabetes is a complex metabolic disease, primar-
ily characterised by insulin resistance, relative insulin
deficiency and hyperglycemia [1]. According to the
Diabetic Atlas 2009 published by the International Dia-
betic Federation, the prevalence of type 2 diabetes in
Indian population is estimated to be around 51 million
and India is regarded as the “diabetic capital of the
world” [2]. The high prevalence of diabetes in Asian
Indians and in particular, South Indian population goes
along with higher adiposity, central obesity and high
familial aggregation of diabetes [3]. The genetic basis of
type 2 diabetes also differs considerably from the wes-
tern population and efforts are going on to understand
the genetic nature of type 2 diabetes in South Indian
population [4-6].
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It is a well established fact that type 2 diabetes is
caused by the interplay of a triad which includes the
progressive decline in insulin producing b-cells, an
increase in insulin resistance and increased hepatic
glucose production [7]. In addition to these, evidences
from recent studies also suggest a role for gastrointest-
inal hormones like incretins which include GIP and glu-
cagon-like peptide -1(GLP-1) towards the manifestation
of type 2 diabetes. [8]. GIP is a single 42 amino acid
peptide derived from the post-translational processing of
a 153 amino acid precursor [9]. It is secreted predomi-
nantly by k-cells and released from the upper small
intestine (duodenum and proximal jejunum) in response
to nutrient ingestion, mainly glucose or fat rich meal
[10,11]. This increased level of GIP induces insulin
release from the pancreatic b-cells and is responsible for
about 70% of postprandial insulin secretion [12]. GIP
stimulates glucose-dependent insulin secretion via the
activation of their specific GIP receptors (GIPR)
expressed on the membrane of pancreatic beta cells.
This in turn activates adnenylyl cyclase, phospholipase
A and extracellular kinase (ERK and MAP), as a result
of which, there is a change in the cellular ion flux ulti-
mately aiding insulin secretion from the pancreatic beta
cells [13-18].
In addition to its role in facilitating the release of
insulin from pancreatic beta cells, GIP also promotes
the proliferation of these cells and prevents their apop-
tosis hence preventing beta cell dysfunction. [19]. GIP
has also been shown to stimulate adipocytes to synthe-
sise and release lipoprotein lipase which hydrolyses lipo-
protein associated triglycerides and facilitates its local
uptake as free fatty acids into adipocytes [20]. Subse-
quent studies with GIPR-/- mice revealed that GIP is an
obesity promoting factor. [21-23]. This led to the sug-
gestion that GIPR antagonist may be useful in treating
type 2 diabetes in European population where it is clo-
sely related to obesity and GIPR agonists may give a
good indication with diabetes related to impaired insulin
release, especially in Asia [24]. Though there is no con-
clusive evidence in the literature suggesting an altered
expression of GIP, it has been shown that, in type 2 dia-
betes, the overall incretin effect is reduced and this was
mainly attributed to altered functioning of GIP [25,26].
The physiological role of GIP in insulin release and fat
metabolism combined with the fact that there is a
reduction in the incretin effect in type 2 diabetes makes
GIP and its receptor suitable candidate genes for genetic
association studies in type 2 diabetes. Though many
studies have been undertaken to analyse the role of
common variants in GIPR for association with type 2
diabetes, very rarely have these studies looked at the
common variants in GIP. Inke et al. analysed two SNPs,
rs2291725 (G>A, Ser103Gly) and rs2291726 (A>G, a
putative splice site SNP) in GIP, for association with
traits of the metabolic syndrome in a case- control
study in European population but failed to observe any
significant difference. Further analysis of these two SNPs
to analyze the association with type 2 diabetes proved to
be negative [27]. However, the sample size used to
detect association with type 2 diabetes was small and
this study was carried out only in one population. So it
is important to use a larger study group and also a dif-
ferent population before ruling out the possible associa-
tion of GIP with type 2 diabetes.
In this study, we have used a case-control approach
for analysing three common variants in GIP, rs2291725
(A>G, Ser103Gly), rs2291726 (G>A, intron-exon bound-
ary) and rs937301 (C>T, promoter) using a total of 2000
subjects which includes 1000 (584M/416F) unrelated
cases with type 2 diabetes and 1000 (470M/530F) nor-
moglycemic control subjects belonging to South Indian
population. We also report association analysis of these
SNPs with age of onset of diabetes, Body Mass Index




Blood samples were collected from a total of 1002 unre-
lated patients (584 M & 418 F) visiting the outpatient
section of the endocrinology department at Amrita
Institute of Medical Science (AIMS), Kochi, Kerala dur-
ing the period 2008-2009. The inclusion criteria of
patients for this study were: a) clinically diagnosed as
type 2 diabetes, which includes the scrutinizing of medi-
cal records for symptoms, use of any medication and
measuring the fasting blood glucose levels following the
guidelines of American Diabetes Association [28], b) age
of onset or diagnosis should be less than 60 years, c)
should not have any other metabolic diseases and d)
belonging to Dravidian ethnicity. Blood samples of
patients from outside Kerala and patients migrating
from other parts of the country were not included in
the study. Subjects with monogenic forms of diabetes,
drug induced diabetes or type 1 diabetes were excluded
from the study. All individual and clinical characteristics
of the study subjects like age, age at diagnosis, weight,
height, body mass index (BMI), smoking and alcohol
status, food habits, whether using insulin or not, family
history of diabetes, fasting blood sugar, lipid profile and
Creatinine values were taken and documented. When
available, details of diabetes related complications like
diabetic nephropathy, retinopathy and neuropathy were
also recorded. A detailed questionnaire was included
along with the informed consent form and details of
other diseases and medications were taken and
documented.
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Age, sex and ethnicity matched normoglycemic
control subjects were recruited in the study by public
advertisement and by offering screening for diabetic risk
factors and its awareness, from various parts of Kerala
by organizing medical camps. Each of the participants
was administered to a health questionnaire which
included personal and family history of the subjects,
height, weight and blood pressure. Blood pressure was
measured after 5 min rest in the sitting position using
an automated sphygmomanometer. Fasting blood sugar
for all the study participants were checked and docu-
mented. A 2 hour plasma blood sugar (PPBS) was also
checked for the respective subjects and only those sub-
jects with PPBS < 140 mg/dl and a fasting blood sugar
value <110 mg/dl was included in the study. All blood
samples were collected under the supervision of an
attending physician. From the large number of subjects
screened during this study only 1000 (470M/530F)
subjects fulfilled the inclusion criteria for normoglyce-
mic controls. All the selected normoglycemic control
subjects were thoroughly screened for negative family
history of diabetes. More than 500 newly diagnosed dia-
betic cases were reported during this screening. The
inclusion criteria for the healthy controls were: a) should
be above 40 years of age, b) should not have any first
degree relatives with diabetes, c) should not be taking or
have taken any oral hypoglycemic agent or insulin, d)
should not have elevated fasting blood sugar level (>110
mg/dl) and a 2 hour post prandial blood sugar level
>140 mg/dl. Clinical characterisation of the study sub-
jects is summarized in the Table 1.
All the patients and healthy controls were explained
the purpose of the study and the complications of inves-
tigative procedure. 5 ml peripheral blood samples were
collected after they signed the written informed consent.
The study was approved by the institutional ethics com-
mittee [AIMS, Kochi] following the Indian Council of
Medical Research guidelines for handling human
samples.
Genotyping and SNP analysis
Genomic DNA was isolated from patients and healthy
volunteers using salting out method [29]. DNA con-
centration was detected by UV-VIS spectroscopy and
diluted to a final concentration of 100 ng/μl. A total of
3 SNPs in GIP were selected for the current analysis.
rs2291725 and rs2291726 were selected based on a
previous study in European population. Additionally
one more SNP, rs937301 was selected for the analysis
which is a promoter polymorphism with a minor allele
frequency >0.1 in the study population. SNPs were
genotyped by using tetra primer ARMS PCR [30]. Each
PCR reaction was carried out in a total reaction
volume of 15 μl. Primer sequences and PCR conditions
for the three SNPs have been provided in additional
file 1, Table S1. The resultant products obtained after
PCR were separated by electrophoresis on 2.5% agarose
gel containing ethidium bromide and visualised by gel
documentation system (Bio-rad, USA). Allele frequen-
cies for each SNP were calculated by allele counting.
Randomly selected 20% of samples were re-genotyped
for cross validating initial genotypes. In case of unclear
genotyping results, the samples were repeated again in
duplicates till clear genotype was available. Unclear
genotyping results, even after repetition was excluded
from the study. No genotyping error was observed dur-
ing cross validation. Nucleotide sequence and SNP
details were obtained from SNPper http://snpper.chip.
org/ and cross validated with the sequence from NCBI
http://www.ncbi.nlm.nih.gov/.
Statistical Analysis
Allele and genotype frequencies were calculated for the
whole cohort and analysed for any deviation from
Hardy-Weinberg Equilibrium (HWE). HWE analysis was
carried out with help of statistical webpage, http://ihg2.
helmholtz-muenchen.de/cgi-bin/hw/hwa1.pl. Compari-
son of allele frequencies and genotype distributions
between case and control samples were done by Pear-
son’s chi- square test. Clinical variables such as age of
diagnosis, fasting blood sugar, Creatinine and HbA1c
were compared using one-way analysis of variance
(ANOVA). The study population was divided into two
sub-groups based on gender (male/female). The differ-
ence in BMI and lipid profile among different genotypic
individual were assessed using the analysis of covariance
(ANCOVA) to correct for age with respective para-
meters. P < 0.05 was considered to be statistically signif-
icant. All the analysis was performed using the statistical
webpage, VassarStat: Statistical Computation http://
faculty.vassar.edu/lowry/VassarStats.html. Correction for
Table 1 Clinical characterisation of the study population
Characteristics Patients (T2D) Controls
n 1000 1000
Sex (Male/Female) 584/416 470/530
Age (years) 55.7 ± 10.2 51.07 ± 10.2
Age of onset of diabetes (years) 45.08 ± 9.04 NA
BMI (Kg/m2 ) 25.05 ± 3.4 23.09 ± 3.9
FBS (mmol/l) 8.67 ± 3.4 4.9 ± 0.58
HbA1c (%) 8.3 ± 1.8 -
Triglyceride (mmol/l) 1.63 ± 0.83 -
Total cholesterol (mmol/l) 5.02 ± 1.28 -
HDL (mmol/l) 1.19 ± 0.35 -
LDL (mmol/l) 3.05 ± 1.02 -
n: number of total subjects
Values are expressed as mean ± SD
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multiple testing was done by Bonferroni’s inequality
method wherever applicable.
Results
Allele frequency and genotype distribution
Initial genotyping in 300 case samples and an equal num-
ber of control samples revealed that the two SNPs,
rs2291726 and rs937301 are in complete LD with each
other in our study population. So for further analysis only
rs2291726 was genotyped. The genotype distributions of
the two gene variants in GIP (rs2291725 and rs2291726)
did not show significant variation from Hardy-Weinberg
proportions. The allele frequency and genotype distribu-
tion of both the SNPs in cases and controls have been
summarised in Table 2. The allele frequencies for the
major and minor allele of rs2291725 were 0.56 and 0.44
respectively in patients as compared to 0.57 and 0.43
respectively in controls (OR = 1.022 [0.902-1.159], P =
0.728) whereas, the allele frequencies in the case of
rs2291726 for the major and minor allele were 0.53 and
0.47 respectively in patients as compared to 0.53 and 0.47
respectively in controls (OR = 0.998 [0.881-1.130], P =
0.974). No significant difference between the genotype
groups were observed in both the SNPs (rs2291725 and
rs2291726) among cases and controls. We also tested
whether there is any significant difference in a dominant
or negative model for both the SNPs but failed to observe
any statistically significant difference.
Association analysis with diabetes related biochemical
parameters
Association analysis of SNPs in GIP with biochemical
parameters was done by using ANCOVA. For associa-
tion analysis of serum lipid levels only those subjects
who were not taking any cholesterol modulating drug
based on the health questionnaire during sample collec-
tion were included for the analysis. We found a signifi-
cant association of the SNP rs2291726 with total
cholesterol and LDL in female subjects. However this
association was observed only in female subjects and did
not achieve the desired significance level after correction
for multiple testing [p = 0.06 (p × 15 tests)]. LDL
showed a stronger association with the SNP rs2291726
(P = 0.004) than total cholesterol (P = 0.04). Interest-
ingly we did not observe this trend in male subjects and
also we did not observe any significant difference when
we did a combined analysis (male and female). There
was no significant association of the SNP rs2291725
with total cholesterol and LDL in males or females.
We also analysed whether the two SNPs have any role
in measures of Fasting blood sugar (FBS) or BMI but
failed to observe any significant association. Creatinine
values also did not show any significant difference
between the three genotypes in both the SNPs. And
finally we analysed whether these SNPs play a role in
early age of onset of diabetes in this population but did
not observe any significant difference between the three
genotypes in both the SNPs. The results for association
analysis with biochemical parameters has been sum-
marised in Table 3 and Table 4.
Discussion
In this study, we did a case-control analysis of common
variants (rs2291726 and rs2291725) in GIP with type 2
diabetes in a South Indian population. After genotyping
1000 type 2 diabetic samples and 1000 control samples,
we failed to observe any significant association of these
SNPs with type 2 diabetes in our population. An asso-
ciation study in one of the European population also did
not reveal any significant association of these SNPs with
traits of metabolic syndrome or with type 2 diabetes,
though the sample size to detect an association with
type 2 diabetes was low [27]. Since the role of GIP in
the manifestation of type 2 diabetes seems to be differ-
ent among Europeans and Asians it is important to
replicate association studies of GIP in Asian population
as well [24].
Table 2 Association analysis of GIP SNPs with Type 2
Diabetes
rs2291725 rs2291726
Major allele A G
Minor allele G A
Controls
n 998 1000
Major homozygous 325 297
Hetrozygous 481 472
Minor homozygous 192 231
Major allele frequency 0.57 0.53
Minor allele frequency 0.43 0.47
HWE (P -value) 0.555 0.100
Cases (T2DM)
n 989 1000
Major homozygous 326 283
Hetrozygous 458 501
Minor homozygous 205 216
Major allele frequency 0.56 0.53
Minor allele frequency 0.44 0.47
HWE (P -value) 0.060 0.837
Tests for association (C.I.: 95% confidence interval)
Odds ratio 1.022 0.998
Allele frequency 0.728 0.974
Dominant model 0.850 0.490
Recessive model 0.406 0.421
n: total number of subjects
HWE - Hardy-Weinberg equilibrium
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Table 3 Association analysis of SNPs rs 2291725with biochemical parameters in diabetes
AA GA GG TOTAL P P*
Age of on set of diabetes (years) 44.64 ± 9.14 45.88 ± 8.77 44.16 ± 9.45 45.13 ± 9.05 0.064 NA
Fasting Blood Glucose (mmol/l) 8.77 ± 3.02 8.675 ± 3.76 8.50 ± 3.34 8.67 ± 3.44 0.726 NA
BMI (Kg/m2)
Male 24.26 ± 3.08 24.53 ± 3.37 24.57 ± 2.95 24.46 ± 3.19 0.664 0.671
Female 25.92 ± 3.67 26.08 ±3.41 26.16 ± 3.65 26.04 ± 3.54 0.896 0.905
Total Cholesterol (mmol/l)
Male 4.97 ± 1.22 4.95 ± 1.28 4.98 ± 1.11 4.96 ± 1.23 0.980 1.000
Female 5.28 ± 1.28 5.08 ±1.27 5.02 ± 1.02 5.14 ± 1.22 0.404 0.366
Triglyceride (mmol/l)
Male 1.69 ± 0.91 1.59 ± 0.80 1.64 ± 0.81 1.63 ± 0.89 0.601 0.691
Female 1.56 ± 0.64 1.63 ± 0.78 1.67 ± 0.81 1.62 ± 0.74 0.684 0.779
HDL (mmol/l)
Male 1.19 ± 0.50 1.15 ± 0.34 1.15 ± 0.26 1.16 ± 0.38 0.677 0.684
Female 1.23 ± 0.29 1.23 ± 0.31 1.28 ± 0.25 1.24 ± 0.29 0.607 0.583
LDL (mmol/l)
Male 2.93 ± 0.89 3.09 ± 1.06 3.08 ± 0.94 3.04 ± 0.99 0.344 0.279
Female 3.27 ± 1.03 3.13 ±0.98 3.04 ± 0.81 3.25 ±0.97 0.362 0.318
HbA1c (%) 8.44 ± 1.98 8.33 ± 1.78 8.21 ± 1.75 8.34 ± 1.85 0.549 NA
Creatinine (μmol/l)
Male 102.92 ± 45.40 102.12 ± 29.73 109.67 ± 32.24 103.83 ± 35.98 0.238 NA
Female 84.29 ± 24.53 82.06 ± 20.37 84.93 ± 27.29 83.49 ± 23.44 0.684 NA
* P value adjusted for age, Number of sample analysed for lipid profile - Male= 411, Female- 250, Creatinine - Male-450, Female- 280. NA: Not Applicable. Datas
are expressed as mean ± SD
Table 4 Association analysis of SNPs rs 2291726 with biochemical parameters in diabetes
AA AG GG TOTAL P P*
Age of on set of diabetes (years) 44.04 ± 8.69 45. 24 ± 8.82 45.02 ± 8.53 44.92 ± 8.72 0.287 NA
Fasting Blood Glucose (mmol/l) 8.572 ± 3.23 8.709 ± 3.45 8.61 ± 3.10 8.65 ± 3.31 0.869 NA
BMI (Kg/m2)
Male 24.21 ± 2.98 24.64 ± 3.38 24.29 ± 2.99 24.45 ± 3.19 0.419 0.415
Female 26.31 ± 3.86 26.01 ± 3.46 25.83 ± 3.42 26.02 ± 3.54 0.691 0.719
Total Cholesterol (mmol/l)
Male 5.07 ± 1.15 4.97 ± 1.28 4.86 ± 1.19 4.96 ± 1.23 0.477 0.549
Female 4.89 ± 1.05 5.09 ± 1.29 5.41 ± 1.21 5.13 ± 1.23 0.050 0.042
Triglyceride (mmol/l)
Male 1.68 ± 1.03 1.61 ± 0.81 1.70 ± 0.93 1.65 ± 0.89 0.632 0.533
Female 1.59 ± 0.79 1.67 ± 0.81 1.55 ± 0.55 1.62 ± 0.74 0.538 0.578
HDL (mmol/l)
Male 1.16 ± 0.26 1.16 ± 0.34 1.17 ± 0.51 1.16 ± 0.38 0.990 0.990
Female 1.29 ± 0.25 1.29 ± 0.31 1.24 ± 0.29 1.24 ± 0.29 0.309 0.321
LDL (mmol/l)
Male 3.09 ± 0.99 3.09 ± 1.05 2.84 ± 0.85 3.03 ± 0.99 0.097 0.152
Female 2.89 ± 0.85 3.11 ± 0.98 3.43 ± 0.98 3.16 ± 0.97 0.005 0.004
HbA1c (%) 8.288 ± 1.76 8.388 ± 1.83 8.33 ± 1.98 8.35 ± 1.85 0.869 NA
Creatinine (μmol/l)
Male 111.05 ± 37.45 106.75 ± 43.04 99.94 ± 39.25 105.81 ± 40.99 0.119 NA
Female 83.97 ± 27.27 81.58 ± 17.26 85.01 ± 25.48 83.16 ± 22.37 0.507 NA
* P value adjusted for age, Number of sample analysed for lipid profile - Male= 411, Female- 250, Creatinine - Male-450, Female- 280. NA: Not Applicable. Datas
are expressed as mean ± SD
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GIP is known to increase fat uptake by promoting the
synthesis and secretion of lipoprotein lipase, which in
turn breaks down triglyceride to free fatty acids, readily
available for local uptake [20]. Infact it has been seen that
mice lacking GIPR did not gain weight and develop adip-
osity in high fat fed conditions and also utilised fat as the
preferred source of energy. This suggests that GIP is an
obesity promoting factor [21,22]. At the same time GIP is
known to promote the release of insulin upon nutrient
ingestion and thus helps in maintaining a proper blood
glucose homeostasis [12,31,32]. In Europeans, who are
more prone to obesity induced diabetes, blocking of GIP
action on adipocytes may be more beneficial whereas it
has been suggested that in Asians, GIP agonists may have
a beneficial effect due to greater incidences of diabetes
with impaired insulin secretion [24]. Though we did not
observe any significant association of the studied poly-
morphisms with type 2 diabetes in our study population,
we suggest a detailed genetic analysis of SNPs in GIP in
other Asian populations as well.
To know more about the genetic role of these variants,
we extended our studies to the biochemical parameters
associated with type 2 diabetes. Interestingly, our associa-
tion studies revealed a significant association of the SNP
rs2291726 with total cholesterol (P = 0.042) and LDL (P
= 0.004) in females. But this association was not observed
in males or during combined analysis (males and
females). Sex related association is not a unique phenom-
enon and there have been studies which report sex
dependent association of polymorphism in genes related
to cholesterol metabolism suggesting a possible role of
sex hormones [33]. Infact it has been shown that estro-
gen has an important role in regulating serum cholesterol
levels and results in a lowering of LDL cholesterol and
triglycerides and hence relatively protects younger
women from cardiovascular diseases [34]. It is interesting
to note that a study by Isken et.al. in mice has shown an
interactive role of estrogen and GIP signalling in obesity
but the molecular mechanism involved in this interaction
still needs elucidation. The study reported that GIPR-/-
mice were resistant to ovariectomy induced obesity [35].
It has also been proposed that hormonal therapy in post
menopausal women can significantly alter the enteroin-
sular axis which also involves GIP [35]. GIP has also been
shown to play an important role in fat metabolism
related diseases like non-alcoholic fatty liver disease
(NAFLD) and due to its important role in cholesterol
metabolism, an altered expression or function of GIP
may play a role in the pathogenesis of cardiovascular dis-
eases as well [36,37]. In our study we observed a signifi-
cant association (P = 0.004) of LDL cholesterol with the
SNP rs2291726 in GIP which is in complete LD with the
promoter polymorphism rs937301, but the association
was observed only in case of female subjects suggesting a
role for sex hormones in this process. Though the asso-
ciation failed to reach the desired significance level after
correction for multiple testing (P = 0.06), it should be
noted that the number of female subjects included in the
analysis for LDL levels were comparatively less (n = 250).
Hence, we suggest further studies in other population
with a higher sample size for the analysis of the role of
this variant and LDL cholesterol levels particularly in
female subjects. It is also interesting to note that post
menopausal women are at a higher risk of cardiovascular
diseases. LDL being the bad cholesterol is a major risk
factor for cardiovascular disease and our study warrants
the need of further association studies in other popula-
tion and functional studies of GIP in relation to estrogen
to better understand its role in cholesterol metabolism
and cardiovascular diseases. An earlier study in European
population looked at the role of common variants in
GIPR and GIP with cardiovascular diseases. But no signif-
icant association was observed between these common
variants and cardiovascular diseases. The study did report
a positive association of the GIPR SNP with HDL but no
results was provided for association analysis of biochem-
ical parameters in diabetes and SNPs in GIP [27].
A recent paper by Juris et al. analysed the expression,
metabolism and clearance of GIP in human with renal
insufficiency [38]. They observed an increased expres-
sion of GIP in cases of renal insufficiency. This led us
to analyse the association of these SNPs with serum
creatinine levels. We also looked at whether these
SNPs are associated with diabetic nephropathy in a
study population of 400 subjects comprising of 184
subjects with renal insufficiency and 216 control sub-
jects (data not shown). We did not find any significant
association with either serum creatinine or diabetic
nephropathy.
Conclusion
The present study indicates that there is no significant
association between the GIP SNPs, rs2291725, rs2291726
and rs937301 and type 2 diabetes in a South Indian Dra-
vidian population. The result of association analysis of
the biochemical parameters of SNP rs2291726 shows a
significant association with total cholesterol and LDL in
the female subjects suggesting a role for sex hormones in
the process but the association does not remain signifi-
cant after correction for multiple testing
Additional material
Additional file 1: Primer sequence and PCR conditions for
amplification of GIP SNPs. Oligoneucleotide sequence and PCR
condition for the allele specific genotyping of three SNPs in GIP.
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